- Home
- USEA vs SNSE Comparison
USEA vs SNSE Comparison
Compare USEA & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- SNSE
- Stock Information
- Founded
- USEA 2004
- SNSE 2005
- Country
- USEA Greece
- SNSE United States
- Employees
- USEA N/A
- SNSE N/A
- Industry
- USEA Marine Transportation
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- SNSE Health Care
- Exchange
- USEA Nasdaq
- SNSE Nasdaq
- Market Cap
- USEA 10.5M
- SNSE 9.3M
- IPO Year
- USEA N/A
- SNSE 2021
- Fundamental
- Price
- USEA $1.28
- SNSE $0.32
- Analyst Decision
- USEA Strong Buy
- SNSE Strong Buy
- Analyst Count
- USEA 1
- SNSE 4
- Target Price
- USEA $6.00
- SNSE $4.25
- AVG Volume (30 Days)
- USEA 23.3K
- SNSE 131.6K
- Earning Date
- USEA 05-22-2025
- SNSE 05-06-2025
- Dividend Yield
- USEA 3.13%
- SNSE N/A
- EPS Growth
- USEA N/A
- SNSE N/A
- EPS
- USEA N/A
- SNSE N/A
- Revenue
- USEA $42,595,000.00
- SNSE N/A
- Revenue This Year
- USEA N/A
- SNSE N/A
- Revenue Next Year
- USEA $11.02
- SNSE N/A
- P/E Ratio
- USEA N/A
- SNSE N/A
- Revenue Growth
- USEA N/A
- SNSE N/A
- 52 Week Low
- USEA $1.00
- SNSE $0.25
- 52 Week High
- USEA $2.84
- SNSE $0.87
- Technical
- Relative Strength Index (RSI)
- USEA 50.08
- SNSE 42.64
- Support Level
- USEA $1.22
- SNSE $0.27
- Resistance Level
- USEA $1.31
- SNSE $0.33
- Average True Range (ATR)
- USEA 0.07
- SNSE 0.04
- MACD
- USEA 0.00
- SNSE -0.00
- Stochastic Oscillator
- USEA 40.84
- SNSE 46.61
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).